Co-production of Classes A and B Carbapenemases BKC-1 and VIM-2 in a Clinical Pseudomonas Putida Group Isolate from Brazil.
Amanda Yaeko YamadaAndreia Rodrigues de SouzaMarisa de Jesus de Castro LimaAlex Domingos ReisKaroline Rodrigues CamposAmanda Maria de Jesus BertaniLeonardo Jose Tadeu de AraujoClaudio Tavares SacchiMonique Ribeiro Tiba-CasasCarlos Henrique CamargoPublished in: Current microbiology (2022)
Emergence of resistance to classical antimicrobial agents is a public health issue, especially in countries with high antimicrobial consumption rates. Carbapenems have been employed as first-choice option for empirical treatment complicated infections. However, in the last decades, frequency of carbapenemase-producing Gram-negative bacteria has rising, demanding the use of alternative antimicrobial agents. By sequencing the entire genomes with short and long reads technologies, we report the isolation and genomic characterization of a carbapenem-resistant Pseudomonas clinical isolate. The identification based on average nucleotide identity indicates a putative new species into the Pseudomonas putida Group, which carries both the bla BKC-1 and bla VIM-2 carbapenemase genes. The bla BKC-1 was found to be on a transferable IncQ plasmid backbone, whereas bla VIM-2 was found in a new integron, In2126 (intl1∆-bla VIM-2 -aacA7-bla VIM-2 ∆-aacA27-3'CS), described in this study. Our findings indicate that co-occurrence of classes A and B carbapenemase enzymes underscores the evolving emergence of more complex antimicrobial resistance in opportunistic pathogens.